Spots Global Cancer Trial Database for Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Official Title: A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)
Study ID: NCT02026063
Conditions
Interventions
Study Description
Brief Summary: The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Lexicon Investigational Site, Mobile, Alabama, United States
Lexicon Investigational Site, Stanford, California, United States
Lexicon Investigational Site, Iowa City, Iowa, United States
Lexicon Investigational Site, Lexington, Kentucky, United States
Lexicon Investigational Site, Boston, Massachusetts, United States
Lexicon Investigational Site, New York, New York, United States
Lexicon Investigational Site, Philadelphia, Pennsylvania, United States
Lexicon Investigational Site, St. Leonards, New South Wales, Australia
Lexicon Investigational Site, Herston, Queensland, Australia
Lexicon Investigational Site, East Melbourne, Victoria, Australia
Lexicon Investigational Site, Edegem, , Belgium
Lexicon Investigational Site, Ghent, , Belgium
Lexicon Investigational Site, Yvoir, , Belgium
Lexicon Investgational Site, Calgary, Alberta, Canada
Lexicon Investigational Site, Halifax, Nova Scotia, Canada
Lexicon Investigational Site, Lille, , France
Lexicon Investigational Site, Lyon, , France
Lexicon Investigational Site, Villejuif, , France
Lexicon Investigational Site, Bad Berka, , Germany
Lexicon Investigational Site, Berlin, , Germany
Lexicon Investigational Site, Essen, , Germany
Lexicon Investigational Site, Hamburg, , Germany
Lexicon Investigational Site, Marburg, , Germany
Lexicon Investigational Site, Jerusalem, , Israel
Lexicon Investigational Site, Milano, , Italy
Lexicon Investigational Site, Milano, , Italy
Lexicon Investigational Site, Pisa, , Italy
Lexicon Investigational Site, Torino, , Italy
Lexicon Investigational Site, Amsterdam, , Netherlands
Lexicon Investigational Site, Noord Holland, , Netherlands
Lexicon Investigational Site, Noord-Brahant, , Netherlands
Lexicon Investigational Site, Barcelona, , Spain
Lexicon Investigational Site, Madrid, , Spain
Lexicon Investigational Site, Seville, , Spain
Lexicon Investigational Site, Lund, , Sweden
Lexicon Investigational Site, Uppsala, , Sweden
Lexicon Investigational Site, Coventry, , United Kingdom
Lexicon Investigational Site, Glasgow, , United Kingdom
Lexicon Investigational Site, London, , United Kingdom
Lexicon Investigational Site, London, , United Kingdom
Lexicon Investigational Site, London, , United Kingdom
Lexicon Investigational Site, Manchester, , United Kingdom
Lexicon Investigational Site, Newcastle-Upon-Tyne, , United Kingdom
Contact Details
Name: Pablo Lapuerta, MD
Affiliation: Lexicon Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
